The maximum retail prices of the following non-scheduled cancer formulations have been lowered by a whopping 87%. This decision reflects the Indian government’s commitment to provide affordable drugs for the treatment and increase access to the large population which is in continuation of the efforts to bring down drug prices.
The prices of Pemxcel injections received the highest cut ranging between 87% and 90%, while Erlotaz price reduction was above 70% for both 100 mg and 150 mg tablets pack of 10.
Earlier this year in February the NPPA had capped 42 non-scheduled oncology drugs which were capped at 30% maximum trade margin. After which over 70 formulations and close to 400 brands reduced the drug prices.
– Vivek Sharma,
Manager – Healthcare Market Research,